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Background: Most tympanic membrane (TM) perforations heal spontaneously, but approximately 10-20% remain
open as chronic TM perforations. Chronic perforations can lead to an impaired hearing ability and recurrent middle
ear infections. Traditionally, these perforations must be surgically closed, which is costly and time consuming. Therefore,
there is a need for simpler therapeutic strategies. Previous studies by us have shown that plasminogen (plg) is a potent
pro-inflammatory regulator that accelerates cutaneous wound healing in mice. We have also shown that the healing of
TM perforations is completely arrested in plg-deficient (plg−/−) mice and that these mice develop chronic TM perforations.
In the present study, we investigated the therapeutic potential of local plg injection in acute and chronic TM perforation
mice models.
Methods: Plg−/− mice and wild-type mice were subjected to standardized TM perforations followed by local injection of
plg into the soft tissue surrounding the TM. TM perforations with chronic characteristics were induced by leaving TM
perforations in plg−/− mice untreated for 9 days before treatment. The healing process was observed through
otomicroscope and finally confirmed by immunostaining. The quality of TM healing was evaluated based on the
morphology of the TM.
Result: Daily local injections of plg into the soft tissue surrounding the TM restored the ability to heal TM perforations in
plg−/− mice in a dose-dependent manner, and potentiated the healing rate and quality in wild-type mice. A single local
injection of plg initiated the healing of the chronic-like TM perforations in these mice, resulting in a closed TM with a
continuous but rather thick outer keratinocyte layer. However, three plg injections led to a completely healed TM with a
thin keratinizing squamous epithelium covering a connective tissue layer.
Conclusion: Our data suggests that plg is a promising drug candidate for the treatment of chronic TM perforations
in humans.
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Tympanic membrane (TM) perforations have a variety
of causes, including trauma, middle ear infection and
iatrogenic injury [1-3]. Most acute TM perforations heal
spontaneously, but approximately 10-20% do not heal and
become chronic [4]. Chronic perforations can lead to im-
paired hearing and recurrent middle ear infections [5]. To
date, myringoplasty, a surgical procedure in which the TM* Correspondence: tor.ny@medchem.umu.se
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stated.is reconstructed by grafting new tissues in the perforated
area, has been the traditional method of repairing chronic
perforations [6]. However, the cost of this surgery, and the
care and sick leave required after surgery, impose a large
burden on both the patients and the healthcare system.
Therefore, simpler therapeutic strategies are being investi-
gated. In this context, several studies throughout the last
decade have sought to identify molecules that may initiate
the healing of TM perforations without surgery [7]. In the
present study, we show that the plasma protein plasmino-
gen (plg) is a new drug candidate for the treatment of
non-healing TM perforations.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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maintained in the blood at a concentration of 2 μM [8].
Plg is activated to the broad-spectrum protease plasmin
by either of two physiological plasminogen activators (PAs):
tissue-type PA (tPA) or urokinase-type PA (uPA) [9]. It has
been well established that plg, due to its ability to degrade
fibrin and extracellular matrix proteins, plays an important
role in fibrinolysis and in many tissue-remodeling processes
including wound healing [9,10]. In addition, we have re-
cently shown that plg is also a potent pro-inflammatory
regulator that accumulates in cutaneous wounds and is
essential for wound healing. In plg−/− mice, cutaneous
wounds do not heal and become chronic, partially due to
a disturbed inflammatory phase. In these mice, wounds
can heal completely only after plg supplementation. Im-
portantly, plg administration also enhances the healing of
acute cutaneous wounds in wild-type (WT) mice and ini-
tiates and allows the complete healing of chronic diabetic
wounds in diabetic mice [11].
Earlier studies from our group have shown that the heal-
ing of TM perforations is completely arrested in plg−/−
mice and that intravenous supplementation of these mice
with human plg restored their ability to heal TM perfora-
tions [12]. We have also shown that active plasmin is im-
portant for TM healing and that uPA, but not tPA, plays a
central role in the activation of plg to plasmin [13]. These
data suggest that plg is essential for the healing of TM per-
forations. Our finding that plg is a pro-inflammatory regu-
lator that enhances cutaneous wound healing in WT and
diabetic mice suggested that plg supplementation might be
a potential treatment for chronic TM perforations. How-
ever, the main difference between the healing of TM per-
forations and the healing of skin wounds is the lack of a
fibrin-rich provisional matrix in TM wounds. Therefore,
during TM healing keratinocytes do not have to migrate
through extracellular matrix beneath the wound crust [12].
In the present study, we used the well-established TM
perforation model to test the effect of plg on the effi-
ciency of healing in plg−/− mice and WT mice. Our re-
sults showed that local injection of plg into plg−/− mice
enhanced healing in a dose-dependent manner. With the
optimal plg dosage, the TM healing in plg−/− mice was
completely rescued, and the healing rate in WT mice was
accelerated. In summary, these data provide a basis for fu-
ture development of plg as a new drug for the treatment
of chronic TM perforations in humans.
Methods
Animals
Plg-heterozygous mice with a C57BL/6 background were
used to generate wild-type (WT), plg-heterozygous (plg+/−)
and plg-deficient (plg−/−) offspring. The mice were geno-
typed using a rapid chromogenic assay as described previ-
ously, and the genotypes were confirmed using PCR [14].WT and plg−/− siblings at the age of 6–8 weeks were used
for the experiments. All of the research protocols were in
compliance with the University of Umeå Ethical Commit-
tee for Animal Studies.
Anesthetizing procedure
The mice were anesthetized by an intraperitoneal in-
jection of a 1:1 mixture of Dormicum® (25 μl, Roche
AB, Stockholm, Sweden) and Hypnorm™ (25 μl, Janssen
Pharmaceutica, Beerse, Belgium) in 50 μl of sterile water.
Perforation procedure
The mice received TM perforations as described previ-
ously [12]. Briefly, the mice were first anesthetized using
the Dormicum and Hypnorm mixture. Under an otomi-
croscope, the pars tensa of the TM was perforated in the
posterior superior quadrant using a myringotomy lancet.
To induce TM perforations with chronic characteristics,
TM perforations of plg−/− mice were performed as de-
scribed above, after which the perforations were left un-
touched for 9 days.
Local injection procedure
The mice were anesthetized using the Dormicum and Hyp-
norm mixture. Under an otomicroscope, 20 μl of human
plg at different concentrations (Omnio AB, Umeå, Sweden)
or phosphate-buffered saline (PBS) was injected into the
surrounding soft tissue at the internal end of the external
ear canal (shown in Figure 1). The course of healing was
observed and documented daily.
Subcutaneous injection procedure
The mice were anesthetized as described above and then
injected at a dorsal subcutaneous site between the back
limbs with 100 μl of 10 μg/μl human plg or PBS.
Intraperitoneal injection procedure
The mice were held by the nape of the neck and extended
by pressing the tail to the palm of the hand. Then, 100 μl of
10 μg/μl human plg was injected. The abdominal wall was
penetrated in a line parallel with the mouse backbone and
at an approximately 45-degree angle to the abdominal wall.
Preparation of specimens for immunohistochemistry
The mice were first sacrificed, and then the skulls were
placed in a 4% buffered formalin solution (pH 7.2) for
approximately 1 week. The buffered formalin solution
contained 0.0027 M KCl, 0.0015 M KH2PO4, 0.1369 M
NaCl, and 0.0080 M Na2HPO4. Thereafter, the TMs and
surrounding bony rim were dissected out and immersed
in phosphate buffer (pH 7.4) overnight. The specimens
were then decalcified. Subsequently, they were soaked in
phosphate buffer for 1 h. After dehydration in a graded
series of ethanol, the specimens were embedded in paraffin.
Figure 1 Simplified schematic diagram showing the local
injection procedure.
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Leica Microtome (Leica Microsystems AB, Kista, Sweden).
The sections were placed on Super Frost Plus glasses slides.
Before the staining procedure, the slides were left in a heat-
ing cabinet at 37°C overnight.
Immunohistochemistry
The paraffin-embedded sections were rehydrated and then
treated with antibodies as follows: cytokeratin was de-
tected immunohistochemically by the peroxidase anti-
peroxidase method using a rabbit anti-human polyclonal
antibody (10550, ICN Pharmaceuticals, Aurora, OH) as
the primary antibody. In brief, the antigens were first re-
trieved by treatment with 0.1% trypsin (pH 7.8) at 37°C
for 8 min, and then the tissue sections were blocked with
5% non-immunized swine serum (Dakopatts, Sweden),
and incubated with the primary antibody, which was
diluted 1:100 in PBS. After this procedure, a swine anti-
rabbit link antibody (Dako, Glostrup, Denmark) was
applied, followed by a rabbit PAP complex (Dako). The
staining was visualized through a diaminobenzidine (DAB)
reaction (Vector Laboratories, Burlingame, CA) and the
sections were counterstained with Mayer’s hematoxylin.
The slides were examined by light microscopy under a
Leica DMLB microscope, and images were recorded digit-
ally using a Leica DC 300 F camera connected to a personalcomputer. Adjustment of the contrast and brightness in the
individual images was performed using Adobe Photoshop
7.0 software.
Scoring of TM healing
A scoring system was used to evaluate the quality of the
healing of the TM perforations. Using the arbitrary scale
shown in Figure 2A, the scoring system comprised four
levels, from an open perforated TM that is given a score
of 0 to a perfectly closed perforation with a thin TM that
is given a score of 3. The keratin-stained TM sections
were scored by two “blind” investigators.
Statistical analysis
In Tables comparisons between groups were analyzed by
Chi-square test. In Figures the results are expressed as a
scatter dot plot. The mean value is indicated as a line.
Comparisons between two groups were performed using
the Mann–Whitney U-test. P < 0.05 was considered to
be significant.
Results
Local plg injection has a dose-dependent effect on the
healing of TM perforations in plg−/− mice
Previous studies by our group have shown that the healing
of TM perforations is completely arrested in plg−/− mice,
but intravenous administration with plg restores the TM
healing ability in these mice [12]. To further investigate
the role of plg in the healing of TM perforations, we stud-
ied whether local plg injection could also restore the heal-
ing of TM perforations in plg−/− mice and if so whether
plg stimulated healing in a dose-dependent manner. Plg−/−
mice were divided into four groups (Table 1), and stan-
dardized TM perforations were made as described in the
Methods section and previously [12]. In Groups 1 to 3,
the mice were locally injected with 0.4 mg/day, 0.2 mg/
day or 0.1 mg/day of plg, respectively, from day 0 to day 8.
In Group 4, the mice were locally injected with PBS daily
and served as negative controls. In addition, WT mice
were subjected to standardized TM perforations and were
included as a positive control so that healing in non-
treated WT mice could be followed. At day 9, the mice
were sacrificed. All of the TM samples were collected and
further analyzed by immunohistochemistry (IHC) staining.
The formation of a continuous keratinocyte layer is the
hallmark of a healed TM perforation [15]. We therefore
used keratin immunostaining to examine the healing of
TM perforation in these mice. As shown in Table 1, all
of the TM perforations healed in Group 1 and Group 2
(which received 0.4 mg/day and 0.2 mg/day of plg, re-
spectively), and 60% of the perforations were healed in
Group 3 (which received 0.1 mg/day of plg). Consistent
with our previous findings [12,13], all of the perforations
were open in the PBS-treated group, Group 4. In the non-
Figure 2 Characterization of the quality of TM healing in plg−/− mice treated locally with plg. (A) The scoring system used to evaluate the
quality of healing of TM perforations. Scale bar, 400 μm. EEC, external ear canal; MEC, middle ear cavity; TM, tympanic membrane. (B) A
comparison of quality of TM healing with the mean value marked by a line for mice from Group 1 (plg−/− mice injected with 0.4 mg/day of plg)
(squares), Group 2 (plg−/− mice injected with 0.2 mg/day of plg) (open circles), Group 3 (plg−/− mice injected with 0.1 mg/day of plg) (triangles),
non-treated WT control mice (diamonds), and Group 4 (plg−/− mice treated with PBS) (hexagons). The quality of healing was evaluated based on
IHC keratin staining performed at day 9 after TM perforation. NS indicates not significant. P < 0.05 was considered to be significant.
Table 2 Statistical analysis of daily local plg injection in
plg−/− mice
Multiple comparisons P value
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healed. Newly healed TM perforations are thicker than
normal TMs, and these TMs gradually get thinner over
time and revert to the typical appearance [16]. The statis-
tical analysis in Table 2 showed that the differences of
healing rates between different doses were statistically sig-
nificant. The thickness of the TM is a crucial determinant
in assessing the quality of TM healing [17]. We therefore
used a scoring system to evaluate the quality of TM healingTable 1 Dose-dependent healing effect of daily local plg
injection in plg−/− mice
Treatment group Healed TM perforations/
Total TM perforations
Plg−/− mice Group 1 (0.4 mg/day) 10/10 (100%)
Group 2 (0.2 mg/day) 10/10 (100%)
Group 3 (0.1 mg/day) 6/10 (60%)
Group 4 (PBS) 0/10 (0%)
WT mice (non-treated) 6/10 (60%)
Data were analyzed by IHC staining at day 9 after the perforations. The healing
rate was calculated and is shown in parentheses.based on IHC analysis. The scoring system is explained in
Figure 2A. As shown in Figure 2B, there was no significant
difference in the quality of healing between Groups 1 and
2, which received the highest daily doses, but there was
a significant difference in the quality of healing betweenGroup 1 vs. Group 2 N/A
Group 1 vs. Group 3 0.025347$
Group 1 vs. Group 4 < 0.0001$$$
Group 1 vs. WT mice (non-treated) 0.025347$
Group 2 vs. Group 3 0.025347$
Group 2 vs. Group 4 < 0.0001$$$
Group 2 vs. WT mice (non-treated) 0.025347$
Group 3 vs. Group 4 0.003415$
Group 3 vs. WT mice (non-treated) N/A
Group 4 vs. WT mice (non-treated) 0.003415$
Data were analyzed at day 9 after the perforations. $P < 0.05;$$P < 0.001;
$$$P < 0.0001.
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treated with the lowest dose of plg (Group 3) was compar-
able to that of the non-treated WT control group. As
shown previously [12], all of the TMs in the PBS-treated
controls (Group 4) remained open and were therefore
given a score of 0. These results indicated that local plg in-
jection restored the healing ability in plg−/− mice and that
plg treatment exerted a dose-dependent healing effect. The
higher plg dosage not only led to a higher healing rate but
also resulted in a better quality of healing.
Local plg injection accelerates the healing of acute TM
perforations in WT mice
The data presented in the previous section showed that
plg−/− mice treated with an optimal plg dosage had an
even higher healing rate and a better quality of healing
than did non-treated WT mice. Additionally, our studies
of skin wound healing indicate that plg treatment signifi-
cantly improved the healing of skin wounds in WT mice
[11]. We therefore investigated whether plg treatment
has an effect on the healing of acute TM perforations in
WT mice. WT mice were subjected to standardized TM
perforations and thereafter were locally injected with
0.2 mg/day of plg or PBS from day 0 to day 6. The TM
perforations were analyzed daily by otomicroscopy. At
day 7, all TM samples were collected, prepared for IHC
and analyzed following keratin staining. As shown in
Table 3, the daily otomicroscopical analysis revealed that
there was a clear difference in the healing patterns of the
plg-treated group and the PBS-treated group. At day 5
after perforation, otomicroscopical observation indicated
that 14% of the perforations in the plg-treated group were
closed, whereas all perforations in the PBS-treated group
appeared to be open. At day 7 after perforation, otomi-
croscopical observation indicated that 62% of the perfora-
tions in the plg-treated group were closed, whereas only
25% of the perforations appeared to be closed in the PBS-
treated group. IHC keratin staining of TM samples taken
at day 7 for keratin revealed that all of the otomicroscopi-
cally closed perforations in the plg-treated group were
truly healed. The majority of the healed TMs in the plg-
treated group also were relatively thin, with a thin outerTable 3 Otomicroscopical and IHC analysis of local plg
injection treatment for TM perforations in WT mice
Treatment
Otomicroscopical analysis IHC analysis
Day 4 Day 5 Day 6 Day 7 Day 7
Plg-treated
0/21 3/21 8/21 13/21 13/21
(0%) (14%) (38%) (62%) (62%)
PBS-treated
0/12 0/12 1/12 3/12 1/12
(0%) (0%) (8%) (25%) (8%)
P value N/A 0.169686 0.064794 0.041292$ 0.002741$
The closure rate was calculated and is shown in parentheses. $P < 0.05.keratinocyte layer and a rather condensed connective tis-
sue layer with fibroblasts starting to reorganize (Figure 3A).
In contrast, only 8% of the perforations in the PBS-treated
group were healed, and the only healed TM was still very
thick with a massive layer of keratinizing squamous epithe-
lium and a thick connective tissue layer with less well ori-
entated fibroblasts (Figure 3B). The other perforations in
the PBS-treated group, which appeared to be otomicrosco-
pically closed, were still open and were found to be cov-
ered with inflammatory cells and tissue elements when
analyzed using keratin staining (Figure 3C). The quality of
TM healing in the WT mice was further evaluated using
the scoring system described above. Our results showed
that plg treatment resulted in a significantly better quality
of healing than did PBS treatment (Figure 4A). In sum-
mary, these results indicated that local plg injection accel-
erated the healing rate and improved the healing quality of
acute TM perforations in WT mice.
Subcutaneous and intraperitoneal plg injections
accelerate the healing of acute TM perforations in mice
It has been shown that after injury, plg is bound to in-
flammatory cells and are transported to the wound site,
which leads to the accelerated healing of wounds [11]. It
is therefore likely that non-local administration methods
such as subcutaneous and intraperitoneal injections may
also affect wound healing. To test this hypothesis, plg−/−
mice were subjected to standardized TM perforations
and then either injected subcutaneously at a dorsal site
between the back limbs or injected intraperitoneally with
1 mg/day of plg or PBS from day 0 to day 8. At day 9, all
of the TM samples were collected, prepared for IHC and
analyzed following keratin staining. As shown in Table 4,
the healing rates in both subcutaneous plg injection group
and intraperitoneal plg injection group were significantly
faster than their PBS control groups. The healing quality
of plg treated groups was also significantly better than
their PBS controls (Figure 4B). WT mice were examined
in a similar way. The mice were subjected to standardized
TM perforations and either injected subcutaneously or
injected intraperitoneally with 1 mg/day of plg or PBS
from day 0 to day 7. TM samples were collected at day 8.
Even though statistical analysis in WT mice failed to show
significant differences between plg-treated groups and
PBS-treated groups, the tendencies of faster healing and
better healing quality in plg-treated groups are observed
(Table 5 and Figure 4C).
Local plg injection initiates and allows the complete
healing of chronic TM perforations in plg−/− mice
To investigate whether local plg injection can initiate heal-
ing of the chronic TM perforations in plg−/− mice, the TM
perforation model was used. Plg−/− mice were subjected to
standardized TM perforations on day 0 and left untreated
Figure 3 Keratin staining of TMs in WT mice treated locally with plg or PBS for 7 days. (A) A representative section of a healed TM from
the plg-treated group; (B) A representative section of a healed TM from the PBS-treated group; (C) An otomicroscopically closed but unhealed
TM perforation from the PBS-treated group. The arrows indicate the perforation areas. Scale bar, 200 μm. EEC, external ear canal; MEC, middle ear
cavity; TM, tympanic membrane.
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of perforation. As shown previously, these TM perforations
are characterized by high neutrophil infiltration, fibrin and
necrotic tissue deposition, and arrested keratinocyte migra-
tion ([12] and data not shown). On day 10, the mice were
divided into three groups (Table 6). The Group 1 mice
were locally injected with plg (0.2 mg/day) on days 10, 11Figure 4 Characterization of the quality of TM healing in mice. (A) Co
(circles) and the locally PBS-treated group (squares) at day 7 after perforatio
subcutaneous plg-injection group (squares), the subcutaneous PBS-injectio
the intraperitoneal PBS-injection group (diamonds) at day 9 after perforatio
subcutaneous plg-injection group (squares), the subcutaneous PBS-injectio
the intraperitoneal PBS-injection group (diamonds) at day 8 after perforatio
be significant.and 12 and left untreated until the end of the experiment.
The Group 2 mice were given a single plg injection
(0.2 mg) on day 10 and left untreated until the end of the
experiment. The Group 3 mice were locally injected with
PBS on days 10, 11 and 12 and left untreated until the end
of the experiment. At day 19, all of the TM samples were
collected and analyzed following keratin staining.mparison of the quality of TM healing of the locally plg-treated group
n in WT mice. (B) Comparison of the quality of TM healing of the
n group (triangles), the intraperitoneal plg-injection group (circles) and
n in plg−/− mice. (C) Comparison of the quality of TM healing of the
n group (triangles), the intraperitoneal plg-injection group (circles) and
n in WT mice. NS indicates not significant. P < 0.05 was considered to
Table 4 IHC analysis of subcutaneous or intraperitoneal
plg injection treatment for TM perforations in plg−/− mice
Treatment group Healed TM perforations/
Total TM perforations
Subcutaneous PBS injection 0/8 (0%)
Subcutaneous plg injection 4/6 (67%)
P value 0.006285$
Intraperitoneal PBS injection 0/8 (0%)
Intraperitoneal plg injection 6/6 (100%)
P value 0.000183$$
Data were analyzed at day 9 after the perforations. The healing rate was
calculated and is shown in parentheses. $P < 0.05; $$P < 0.001.
Table 6 IHC analysis of local plg injection treatment for
chronic-like TM perforations in plg−/− mice
Treatment group Healed TM perforations/
Total TM perforations
Group 1 (plg injections on day 10, 11 and 12) 3/6 (50%)
Group 2 (plg injection on day 10) 2/6 (33%)
Group 3 (PBS injections on day 10, 11 and 12) 0/12 (0%)
Data were analyzed at day 19 after the perforations. The healing rate was
calculated and is shown in parentheses.
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to 50% of the perforations being healed by day 19, and a
single plg injection (Group 2) resulted in approximately
33% of the perforations being healed by day 19. None of
the perforations in the PBS treated mice (Group 3) had
healed by day 19. The statistical analysis in Table 7 showed
that the healing rates in both Group 1 and Group 2 are sig-
nificantly faster than that in Group 3. As shown in Figure 5,
the TMs were obviously thinner in the mice treated with
three injections (Group 1) (Figure 5A) as compared to
those injected only once (Group 2) (Figure 5B). In the con-
trol group (Group 3) treated with PBS, all of the TM perfo-
rations were open, and the perforation borders were thick
(Figure 5C). These data indicated that even a single plg in-
jection initiated the healing of chronic TM perforations
resulting in a closed TM with a continuous but rather thick
outer keratinocyte layer. However, for better healing of TM
perforations and to obtain good TM morphology, multiple
plg injections are required.
Discussion
In the present study, we demonstrated that local plg in-
jection restored the healing of TM perforations in plg−/−
mice in a dose-dependent manner and enhanced the rate
and quality of healing of acute TM perforations in WT
mice. We also showed that the effect of plg seems to beTable 5 IHC analysis of subcutaneous or intraperitoneal
plg injection treatment for TM perforations in WT mice
Treatment group Healed TM perforations/
Total TM perforations
Subcutaneous PBS injection 3/10 (30%)
Subcutaneous plg injection 5/10 (50%)
P value 0.36131
Intraperitoneal PBS injection 3/10 (30%)
Intraperitoneal plg injection 5/10 (50%)
P value 0.36131
Data were analyzed at day 8 after the perforations. The healing rate was
calculated and is shown in parentheses.independent of the administration method. When chronic
TM perforations are induced in plg−/− mice, a single plg
injection can initiate its healing, resulting in the closure of
the keratinizing squamous epithelium and the growth of
connective tissue. However, three plg injections led to
complete TM healing in which the in-growth of connect-
ive tissue was complete and the epithelium had thinned
out (Figure 5).
TM perforation is a common condition that affects ap-
proximately 3% of the US population and 1% of the popu-
lation worldwide [18]. The majority of these perforations
heal spontaneously; however, approximately 10-20% of
these perforations do not heal and become chronic [4].
The most common way to treat chronic TM perforations
is through surgery. Over the years, various tissues and ma-
terials as well as a variety of surgical procedures have been
used with different success rates [19,20]. However, the
cost of surgery is high and the burden on both the patients
and the healthcare system is great. Therefore, it is import-
ant to find an alternative treatment. To reduce the cost,
surgical risks and hospitalization period, such a treatment
should preferably be a non-surgical out-patient procedure.
Our previous studies of wound healing have shown
that systemic administration of plg restored the arrested
healing of TM perforations in plg−/− mice and acceler-
ated the healing of acute and diabetic skin wounds in
mice [11,12]. However, to apply systemic administration
in humans would require a large amount of plg and for
many reasons not be possible in clinical practice. In the
present study, we demonstrated that complete healing of
TM perforations could be obtained in plg−/− mice fol-
lowing local injection of plg. To use topical application
of plg on TMs would be an even better therapeutic
choice. In fact, our preliminary data in plg−/− mice indi-
cated that TM healing can be obtained following topicalTable 7 Statistical analysis of local plg injection
treatment for chronic-like TM perforations in plg−/− mice
Multiple comparisons P value
Group 1 vs. Group 2 0.558185
Group 1 vs. Group 3 0.00729$
Group 2 vs. Group 3 0.0339$
Data were analyzed at day 19 after the perforations. $P < 0.05.
Figure 5 Keratin staining of chronic-like TM perforations in plg−/− mice treated locally with plg. TM perforations in plg−/− mice were left
untreated for 9 days to acquire the characteristics of chronic wounds. From day 10, plg was locally injected one or three times. The healing of
the perforations was analyzed by IHC at day 19. (A) A representative section of a chronic TM perforation treated with three plg injections on days
10, 11, and 12 (Group 1); (B) A representative section of a chronic TM perforation treated with a single plg injection on day 10 (Group 2); (C) A
representative section of a chronic TM perforation treated with three PBS injections (Group 3). The arrows indicate the perforated areas. Scale bar,
200 μm. EEC, external ear canal; MEC, middle ear cavity; TM, tympanic membrane.
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use of local plg injections or even topical plg applica-
tions may therefore become feasible therapeutic choices
to treat patients with TM perforations.
We also previously showed that plg bound to cell sur-
face receptors on inflammatory cells are transported to
the wound site, where the level of plg is locally increased,
which leads to a pro-inflammatory cell activation and ac-
celerated wound healing [11]. It is known that the binding
of plg to the surface of inflammatory cells can reach a sat-
uration point when the plg concentration increases [21].
In the present study, we found that the effect of plg on the
healing of TM perforation is dose-dependent (Tables 1
and 2, Figure 2). Based on our previous results, it is rea-
sonable to speculate that when a low plg dose is adminis-
tered, less plg is bound to the cells compared to when a
higher dosage is administered, and therefore, less plg is
transported to the wound area. The lower dose therefore
results in non-optimal activation of inflammatory cells
and less pronounced wound healing. When the amount
of injected plg is increased, the maximum binding of
plg to the cells may be reached, and the cell surface
then becomes saturated by plg. This may explain the
dose-dependent and saturated healing effect we observed
(Table 1 and Figure 2B). Furthermore, because plg is trans-
ported to the wound site by inflammatory cells, one can
speculate that different modes of plg administration might
have similar effects on healing. The results obtained in the
present study (Tables 4 and 5, Figure 4B and C) support
this conclusion. Thus, even though plg was not injected lo-
cally, it still stimulated wound healing in a fashion similar
to local injections.
We previously showed that plg−/− mice can be used as
a model system to investigate the healing of chronic TM
perforations [12]. TM perforations in plg−/− mice cannot
heal and acquire the characteristic features of chronic
wounds, which include the accumulation of inflammatorycells, the lack of necrotic tissue debridement, and often,
bacterial infections [12,22]. In the present study, we showed
that even if TM perforations in plg−/− mice have remained
open for 10 days, healing could be initiated by a single plg
injection (Tables 6 and 7, Figure 5). In plg−/− mice that re-
ceived a single injection of plg, necrotic tissue was removed,
and there was no more excessive inflammatory cell accu-
mulation. The keratinocytes that before the plg injections
seemed to lack orientating capacity became re-orientated
after a single plg injection and started to migrate to form a
closed but thick outer keratinocyte layer resting on a thick
layer of loose connective tissue. However, to obtain a healed
TM, with a thin outer keratinocyte layer that more closely
resembled a normalized TM, at least three plg injections
were required. This result suggests that plg is not only im-
portant for the initiation and termination of the inflamma-
tory phase in chronic TM perforations but that plg is also
important for the tissue remodeling that occurs later during
TM healing.Conclusions
We have shown that local injection of plg into the soft
tissue surrounding the TM restored the healing ability of
chronic TM perforations in mice. These data suggest that
plg therapy may become a novel treatment for chronic
TM perforations to be used in clinical practice.Abbreviations
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